Latest Period
n/a
Security Snapshot
Senti Biosciences, Inc. - Common Stock, $0.0001 par value (SNTI) Institutional Ownership
CUSIP: 81726A100
13F Institutional Holders and Ownership History from Q2 2022 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Symbol
- SNTI on Nasdaq
- Shares outstanding
- 31,203,430
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- SNTI - Senti Biosciences, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 81726A100.
- Latest finished 13F holder period is not available.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $357,795 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
81726A100
Latest holder period
n/a
13F holders
13D/G owners
3
CIK / CUSIP context first
SNTI full holder history
Senti Biosciences Holdings, Inc. SEC filings
Senti Biosciences Holdings, Inc. company facts
Senti Biosciences Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81726A100:
Significant Owners of Senti Biosciences, Inc. - Common Stock, $0.0001 par value (SNTI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAYER HEALTHCARE LLC | 20% | $21,561,396 | 6,142,848 | Bayer HealthCare LLC | 10 Mar 2025 | |||
| New Enterprise Associates 15, L.P. | 12% | 3,775,615 | New Enterprise Associates 15, L.P. | 27 Mar 2026 | ||||
| Lonsdale Joe | 1% | 253,755 | 8VC GP I, LLC | 31 Mar 2025 |
Institutional Holders of Senti Biosciences, Inc. - Common Stock, $0.0001 par value (SNTI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$357,795 | 0 | |
| 2025 Q3 | 253,755 | $357,795 | $1.41 | 1 | |
| 2025 Q2 | 253,755 | $535,423 | $2.11 | 1 | |
| 2025 Q1 | 253,755 | $852,617 | $3.36 | 1 | |
| 2024 Q4 | 253,755 | $890,680 | -$108,588 | $3.51 | 1 |
| 2024 Q3 | 301,803 | $682,074 | -$3,229,173 | $2.26 | 2 |
| 2024 Q2 | 7,852,373 | $2,167,022 | -$200,934 | $0.28 | 18 |
| 2024 Q1 | 10,994,171 | $4,145,409 | -$257,675 | $0.38 | 27 |
| 2023 Q4 | 11,461,121 | $7,564,707 | -$1,232,771 | $0.66 | 25 |
| 2023 Q3 | 12,038,399 | $5,018,240 | -$89,453 | $0.41 | 24 |
| 2023 Q2 | 12,200,284 | $7,637,336 | -$267,542 | $0.63 | 27 |
| 2023 Q1 | 12,610,070 | $14,256,476 | +$192,588 | $1.18 | 24 |
| 2022 Q4 | 12,403,151 | $16,580,774 | -$1,583,124 | $1.41 | 26 |
| 2022 Q3 | 13,467,057 | $27,830,384 | +$3,545,876 | $2.17 | 22 |
| 2022 Q2 | 11,903,638 | $22,079,000 | +$22,079,000 | $1.96 | 18 |